Vasculitis and Kidney Involvement: Nephrology vs Rheumatology

Research-informed explainer — last updated April 2026

When vasculitis attacks the kidneys, you need two kinds of specialists — and understanding how they work together can make a real difference in your care. Vasculitis is inflammation of blood vessels, and in certain forms it targets the tiny filtering units inside your kidneys. That means a rheumatologist manages the underlying immune disease, while a nephrologist protects your kidney function. Neither does the other's job alone.

This explainer draws on peer-reviewed research from five rheumatologists listed in the Convene directory: Carol Langford, MD, at Cleveland Clinic, who led and co-authored landmark randomized controlled trials including the RAVE trial comparing rituximab to cyclophosphamide for ANCA-associated vasculitis; Eli Miloslavsky, MD, at Massachusetts General Hospital, whose work spans outcomes by ANCA subtype, remission induction in severe disease, and relapse management; Ashima Makol, M.D., at Mayo Clinic, who studied the efficacy of rituximab and plasma exchange specifically in ANCA vasculitis with severe kidney disease; Kinanah Yaseen, M.D., at Cleveland Clinic, who published clinical reviews of ANCA-associated vasculitis and IgA vasculitis in adults including their kidney manifestations; and Anisha Dua, MD, at Northwestern Medicine, who contributed to research on avacopan, a newer drug that targets the complement pathway and has shown particular benefits for kidney function recovery.

What vasculitis does to the kidneys

Vasculitis is an umbrella term for diseases that cause the immune system to attack blood vessels. When small blood vessels inside the kidneys become inflamed, the filtering units — called glomeruli — get damaged. This can happen gradually or suddenly, and it can range from mild protein leakage in the urine to near-complete kidney failure over days or weeks.

The most common forms that harm the kidneys include:

• ANCA-associated vasculitis (AAV) — a group that includes granulomatosis with polyangiitis (GPA, formerly called Wegener's), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These conditions are defined by circulating antibodies called ANCA (antineutrophil cytoplasmic antibodies), which activate immune cells and trigger vessel inflammation. Kidney involvement is common across this group [8].
• IgA vasculitis — previously called Henoch-Schönlein purpura. In adults, kidney damage from IgA glomerulonephritis can be more severe and persistent than in children [9].
• Drug-induced ANCA vasculitis — certain medications can trigger ANCA production and cause vasculitis that closely resembles the spontaneous forms, including kidney damage [see sources].

For the purposes of this article, ANCA-associated vasculitis with kidney involvement gets the most attention — it is the most common, the most studied, and the form where the rheumatology-nephrology divide is most pronounced.

Why you need both a rheumatologist and a nephrologist

The short answer: the disease has two problems that require different expertise.

A rheumatologist specializes in autoimmune and inflammatory diseases. Vasculitis is an autoimmune disease at its root — the immune system misfires and damages its own tissues. The rheumatologist manages the immunosuppressive drugs that stop the inflammation, interprets the ANCA blood tests, monitors for disease flares, and oversees the long-term treatment plan.

A nephrologist specializes in kidney disease. If vasculitis has reached your kidneys, you need someone tracking your kidney function closely — measuring your glomerular filtration rate (GFR), checking for protein and blood in your urine, and acting quickly if function drops. If kidney damage is severe, the nephrologist may perform a biopsy to confirm the diagnosis and guide how aggressively to treat.

In practice, many academic centers and specialty hospitals manage ANCA vasculitis with a shared-care model where both specialists see the patient together or are in close communication. If you are being treated for vasculitis with kidney involvement and you have only one of these two specialists, it is worth asking your doctor whether the other is needed.

How the type of ANCA antibody affects your prognosis

Not all ANCA-associated vasculitis is the same. Two main subtypes of ANCA exist: PR3-ANCA (associated with proteinase 3) and MPO-ANCA (associated with myeloperoxidase). Research published in the Annals of the Rheumatic Diseases found that outcomes differ meaningfully based on ANCA type — PR3-ANCA positive patients tend to have a higher relapse risk over time [4]. A separate study found that relapse risk tracks more closely with the specific disease manifestation pattern than with ANCA type alone [10], which is why your doctor's clinical assessment matters as much as the lab result.

Why does this matter for kidney involvement? Because higher relapse risk means more episodes of active inflammation, and each episode carries the potential for additional kidney damage. Understanding your ANCA subtype helps your rheumatologist estimate how closely to monitor you and how long to continue maintenance therapy.

At a glance

How remission is induced: the drugs and what the trials showed

The most important decision in treating vasculitis with kidney involvement is how to shut down the inflammation quickly — this is called remission induction. Two drugs have dominated this space for decades: cyclophosphamide, an older immunosuppressant, and rituximab, a biologic that depletes a specific type of immune cell called B cells.

The landmark RAVE trial, published in the New England Journal of Medicine and co-authored by Carol Langford, enrolled patients with severe ANCA-associated vasculitis and compared these two drugs head-to-head. The result: rituximab was non-inferior to cyclophosphamide for inducing remission [1]. More notably, rituximab was superior in patients who were experiencing a relapse rather than a first episode of the disease.

A follow-up study published two years later, also in the New England Journal of Medicine, extended this comparison over 18 months in 197 patients. A single course of rituximab was as effective as 18 months of continuous conventional therapy — including cyclophosphamide followed by azathioprine. Remission rates were 64% for rituximab versus 53% for the conventional arm at six months [2].

The practical implication: for most patients with severe ANCA vasculitis, rituximab and cyclophosphamide are roughly equivalent choices for induction. The decision often depends on patient-specific factors — whether the disease is a relapse (favors rituximab), childbearing plans (cyclophosphamide carries fertility risks), or contraindications to one agent.

What happens when the kidneys are severely affected

Patients whose kidney function has dropped sharply face a harder clinical problem. A 2020 study published in the Journal of the American Society of Nephrology, co-authored by Ashima Makol, specifically examined ANCA vasculitis patients with severe kidney disease — meaning creatinine levels suggesting significant, acute renal impairment. The findings showed that rituximab and cyclophosphamide performed comparably even in this high-stakes subgroup [6]. Importantly, the study also found that adding plasma exchange (a procedure that filters antibodies out of the blood) to standard induction therapy showed no benefit in this cohort. A randomized controlled trial remains the definitive test, but the data available points toward plasma exchange not being routinely necessary for most patients with severe renal involvement.

For about one in four patients, active disease persists or returns within the first six months despite treatment [5]. PR3-ANCA positivity is a known risk factor for this. When a relapse does occur, re-treating with rituximab combined with glucocorticoids has been shown to be safe and effective [10].

The role of glucocorticoids — and what is changing

High-dose steroids (glucocorticoids) have historically been part of every induction regimen for vasculitis, given alongside either cyclophosphamide or rituximab. The problem is that prolonged steroid exposure causes substantial harm: bone loss, diabetes, infections, and weight gain. Contemporary practice has moved toward minimizing cumulative steroid exposure, using rituximab for both induction and maintenance, and seeking alternatives where possible [3].

The most significant recent shift is avacopan, a drug that blocks the complement C5a receptor — a component of the immune cascade that contributes to kidney inflammation in ANCA vasculitis. Research co-authored by Anisha Dua, published in the Annals of the Rheumatic Diseases in 2023, examined avacopan in 214 patients receiving rituximab as background induction therapy; 76.2% had renal involvement at baseline. Sustained remission at 52 weeks reached 71% in the avacopan group versus 56.1% in the prednisone-taper group [7]. Kidney function recovery, measured by eGFR improvement, was better with avacopan, and the avacopan group had fewer steroid-related side effects. The FDA approved avacopan in 2021 for ANCA-associated vasculitis, and it is increasingly used as a steroid-sparing strategy, particularly in patients where kidney protection is a priority.

What maintenance therapy looks like

After remission is achieved, the goal shifts to keeping the disease quiet without the toxicity of induction-level drugs. Rituximab has become the preferred maintenance agent at most centers, given its track record across the induction and relapse literature. Azathioprine and mycophenolate mofetil are alternatives for patients who cannot receive rituximab. For patients without organ-threatening disease, methotrexate is sometimes used [3].

Maintenance duration is debated. The risk of relapse is highest in the first few years after diagnosis, with PR3-ANCA positivity being the clearest predictor of ongoing risk. Many rheumatologists continue maintenance therapy for at least 24 months after remission, monitoring ANCA levels and urine markers along the way. Your nephrologist watches kidney function throughout this period and flags any early sign of a flare before it becomes a crisis.

IgA vasculitis — a different disease with its own kidney challenges

ANCA vasculitis is not the only form that damages kidneys. IgA vasculitis — named for the IgA antibody deposits found in affected tissues — primarily causes a skin rash, joint pain, and abdominal symptoms, but in adults it often involves the kidneys through IgA glomerulonephritis. A review published in Current Rheumatology Reports and co-authored by Kinanah Yaseen described IgA vasculitis in adults as rare but clinically challenging [9]. Kidney disease in this setting is harder to manage than in children, tends to be more severe, and may require immunosuppressive therapy with rituximab or cyclophosphamide when the glomerulonephritis is significant.

IgA vasculitis with kidney involvement also typically warrants co-management between rheumatology and nephrology, with the nephrologist performing the kidney biopsy to grade the severity of IgA deposits and guiding the decision about how aggressively to treat.

Questions to ask your doctors

• Which type of vasculitis do I have, and does it have ANCA antibodies? If so, is it MPO-ANCA or PR3-ANCA?
• Has my kidney function been tested? Is a kidney biopsy needed to confirm involvement?
• Am I being seen by both a rheumatologist and a nephrologist, or should I be?
• Which drug is being recommended for induction — rituximab or cyclophosphamide — and why?
• Is avacopan an option for me to reduce my steroid exposure?
• How will we monitor my kidneys during and after treatment?
• How long will I be on maintenance therapy, and what is the plan if the disease relapses?

The bottom line

Vasculitis with kidney involvement is a two-specialty disease. The rheumatologist manages the immune system; the nephrologist watches the kidneys. For ANCA-associated vasculitis — the most common form to affect the kidneys — the choice between rituximab and cyclophosphamide for induction comes down to disease history, relapse risk, and patient factors rather than one being clearly better than the other. Plasma exchange does not appear to add benefit for most patients with severe kidney disease. Avacopan, a newer complement inhibitor, offers a meaningful alternative to high-dose steroids in patients receiving rituximab and shows particular promise for kidney function recovery. Throughout treatment and maintenance, close monitoring of kidney function remains as important as controlling the inflammatory disease itself.